Send to

Choose Destination
Mol Oncol. 2011 Dec;5(6):538-44. doi: 10.1016/j.molonc.2011.08.002. Epub 2011 Aug 8.

NFIB is a potential target for estrogen receptor-negative breast cancers.

Author information

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea.



The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested.


We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients.


By using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway.


Our results show a potential role of NFIB as a novel target in ER negative breast cancers.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center